The retinoblastoma protein (Rb) 
Introduction
Replication-deficient recombinant adenovirus vectors have been shown to be efficient delivery vehicles for gene transfer both in vitro and in vivo. 1, 2 One limitation to their use in gene therapy, however, has been an inability to confine expression to targeted cells or tissues while maintaining sufficient levels of transgene expression to achieve a desired effect. As more powerful cytostatic or cytotoxic genes are investigated for therapy, dissemination and systemic toxicity become a concern. In addition, when these genes are contained within a virus, the growth of the virus itself in a producer cell line becomes problematic. One solution to systemic and production toxicity is through the use of tissue-specific promoters to restrict transgene expression.
Both the retinoblastoma gene product (Rb) and the transcription factor E2F play critical roles in regulating cell growth (reviewed in Adams and Kaelin 3 ). A truncated, C-terminal derivative of Rb containing amino acids 379-928, designated p56, has been shown to be the mini- mal region necessary to provide for the E2F binding and growth suppressive effects observed with full-length Rb. p56 is a strong inhibitor of cell growth on its own [4] [5] [6] and has been reported to be a more potent inhibitor of E2F-mediated transcription than full length wild-type Rb. 7 E2F normally serves to activate transcription of S-phase genes, but the hypophosphorylated form of Rb is able to arrest cells in G1 by binding E2F to form a complex that functions as a transcriptional repressor. 3 Although E2F binds to Rb in the absence of other factors, complex formation is more efficient if the E2F-related protein DP-1 is present. 8 The observation that fragments of Rb can act as transcriptional repressors when fused to DNA binding proteins such as E2F, 9 suggested that fusions of Rb and E2F fragments could function as potent inhibitors of S-phase transcription. In this report, we describe a hybrid transgene construct consisting of a minimal C-terminal region of Rb containing the E2F-binding pocket domain (designated p56) that is capable of mediating G1 growth arrest. 6 For E2F, we used a fragment that contains the DNA and DP-1 binding pockets, but lacks the transcriptional transactivation domain of full length E2F. The resulting E2F/p56 fusion protein was anticipated to have no transcriptional enhancing activity, but should function as both a transcriptional repressor and an anti-cell cycle agent with a greater potential for growth inhibition than obtained with wild-type Rb or the various fragments of Rb. A recombinant adenovirus was made that expresses the E2F/p56 fusion under the control of a promoter fragment of the human smooth muscle ␣-actin (SMA) gene to provide tissue-specific expression in smooth muscle cells. This promoter contains both positive and negative regulatory regions which act to restrict its expression to specific muscle cell types, [10] [11] [12] thereby avoiding expression of the transgene in non-targeted tissues.
We tested the recombinant adenoviruses encoding either p56 or the E2F/p56 fusion construct under the control of the SMA promoter for their ability to specifically inhibit vascular smooth muscle cell (VSMC) proliferation and neointima formation following balloon-injury in the rat carotid artery model of restenosis. Post-angioplasty and in-stent restenosis are characterized by the rapid proliferation of VSMCs 13,14 and we previously reported that CMV promoter-driven adenoviral constructs expressing either full-length Rb or p56 effectively inhibited neointima formation in the rat model. 6 The results presented here suggest that when the E2F/p56 fusion construct is placed under the control of the SMA promoter, expression occurs in a tissue-specific manner and is efficacious in preventing neointima formation. Therefore, the SMA driven E2F/p56 adenoviral construct may be useful in the treatment of restenosis and, in addition, targeted transgene expression should prove useful for the production of other recombinant viruses, whose transgenes inhibit the growth of viral producer cell lines.
Results

E2F promoter repression by p56 and E2F/p56
The Ad E2 promoter contains two E2F-binding sites and full-length RB can efficiently repress this activity. 15 We have previously demonstrated that a truncated version of Rb, designated p56, is more efficient than full-length Rb at inhibiting the E2F-mediated transcription of this site. 7 In Figure 1 , CMV-driven p56 constructs (pCMVp56, pCMV-p56-5s) were compared with the fusion protein construct of the DNA and DP1-binding domains of E2F linked directly to p56, which is also driven by the CMV promoter (pCMV-E2F/p56). While p56 is a potent repressor of the E2CAT activity, the fusion construct is even more effective, reducing CAT activity to background levels. The E2F control plasmid had no repressor activity alone, but rather stimulated transcription as expected.
Specificity of expression from the human smooth muscle ␣-actin promoter
The specificity of transgene expression from replicationdefective adenoviral vectors using the human smooth muscle ␣-actin promoter was tested in two ways. First, an epithelial-derived breast tumor cell line, MDA MB468, and a rat vascular smooth muscle cell line, A7r5, were infected with either a CMV-or SMA-driven ␤-galactosidase vector and transgene exression was assessed (Figure 2a) . The difference in infectability of the two cell lines is evident in comparing the number of transgenepositive blue cells in culture when infected with equal amounts of the CMV-driven construct. It has been reported previously that cells of epithelial origin, such as the breast carcinoma line, are more efficiently infected by adenovirus than cells originating from muscle. 16 Despite this difference in transduction efficiency, ␤-galactosidase activity was not detected in the highly infectable MDA MB468 cells even at a 100-fold higher dose of the Ad-SMA-␤gal virus. In contrast, at half the dose used for the MDA MB468 cells, ␤-galactosidase-positive cells were readily evident in the A7r5 cells infected with SMA-␤gal, even though VSMCs are more resistant to adenovirus infection. In addition, human umbilical vein endothelial cells or human vascular smooth muscle cells were infected with the two viruses ( Figure 2b ). Here once again the specificity of the SMA promoter is apparent since expression of B-galactosidase from the Ad-SMA␤gal virus was only observed in the human VSMC culture, an important point since inhibition of endothelial replication could have undesirable clinical consequences. From these results it is clear that the SMA-driven construct is selectively active in vascular smooth muscle cells.
Transgene protein expression from Ad-SMA-E2F/p56 and Ad-SMA-p56 was also compared with that expressed by the CMV-driven p56 construct (Ad-CMV-p56) in the two cell lines (Figure 3 ). Here again, smooth muscle-specific protein expression was observed with the SMA constructs. Differences in promoter strength between the CMV and SMA-driven p56 constructs were also evident, in that higher doses of the SMA-driven constructs were required to visualize protein expression in smooth muscle cells. At high viral doses, the non-muscle cells exhibited a small amount of transgene expression from the SMA constructs probably due to the much greater infectability of the MB468 cells.
Inhibition of vascular smooth muscle cell proliferation by SMA-E2F/56 and SMA-56
The Ad-SMA-E2F/p56 and Ad-SMA-p56 constructs were tested for their ability to inhibit 3 H-thymidine incorporation in muscle versus non-muscle cells compared with a CMV-driven p56 virus (Ad-CMV-p56) or control viruses containing either the SMA or CMV promoters (Ad-SMA and Ad-CMV, respectively), but no transgene. As shown in Figure 4 , only the CMV-driven-p56 construct was an effective inhibitor of the breast carcinoma cell line, MB468. In contrast, both the Ad-SMA-E2F/p56 and Ad-SMA-p56 were as effective as the Ad-CMV-p56 construct in inhibiting proliferation of the VSMC line A7r5. The control viruses lacking transgene were inactive in both cell lines, demonstrating a transgene-specific effect.
Flow cytometric analysis of cell cycle progression was also performed on cells infected with either SMA or Gene Therapy CMV-driven constructs. Table 1 lists the results of cell cycle analysis of A7r5 VSMCs and MB468 breast carcinoma cells infected with either Ad-CMV-p56, Ad-SMAp56, Ad-SMA-E2F/p56, or the control viruses lacking transgene, Ad-CMV or Ad-SMA. The CMV-driven p56 (Ad-CMV-p56), SMA-driven p56 (Ad-SMA-p56) and E2F/p56 fusion (Ad-SMA-E2F/p56) constructs all led to an arrest and accumulation of the A7r5 cells in the G0/G1 phase of the cell cycle, while control viruses had G0/G1 values similar to untreated cells. In contrast, only the CMV-driven p56 virus was able to cause a G0/G1 arrest in the non-muscle cell line. These results again show the tissue specificity of the SMA promoter-driven constructs, as well as demonstrating the G0/G1 arrest that would be expected from inhibiting E2F-mediated entry into Sphase.
Expression of ␤-gal following in vivo administration
Since the administration of a therapeutic recombinant adenovirus to the vessel wall is likely to enter systemic circulation, the expression from the SMA-driven construct was analyzed in target and non-target tissues in rats. ␤-Galactosidase expression was examined following in vivo administration of either Ad-CMV-Bgal or Ad-SMA-␤gal to liver, skeletal muscle, bladder and carotid arteries as shown in Figure 5 . While the CMV-␤gal construct was active in each tissue examined following multiple routes of administration, the Ad-SMA-␤gal only displayed transgene expression in the medial layer of the vessel wall. In these vessels transgene expression was not uniform, possibly due to the low sensitivity of ␤-galactosidase detection, particularly in vascular tissue. 17 
Effect of SMA-driven constructs on neointima formation in the balloon-injured rat carotid artery model
Because the SMA-driven p56 and E2F/p56 constructs were able to specifically induce a G0/G1 arrest in VSMCs, we next tested their ability to inhibit hyperproliferation of VSMCs in the rat carotid model of stenosis. We and others have previously reported on the ability of various adenoviral constructs expressing Rb to cause a 39% to 43% decrease in the hyperproliferation of VSMCs that occur following balloon-induced injury in the rat carotid model. 6, 18 Figure 6 results indicate that the Ad-SMA-E2F/p56 fusion construct was able to cause a 37% inhibition of neointima formation relative to either the saline control or Ad-SMA empty control adenovirus (P = 0.0065 and 0.0058, respectively). Although SMA-p56 also caused some inhibition, it was not statistically significant. In all sections examined lesions were observed to be circumferential (data not shown).
Discussion
The local administration of a therapeutic recombinant adenovirus to the vessel wall following balloon angioplasty can lead to viral dissemination and potential systemic toxicity. Thus a transcriptional targeting strategy can attenuate the risk associated with viral dissemination. In this paper, we describe constructs that utililize the vascular smooth muscle-specific (SMA) promoter to express a transgene in the vessel wall, while remaining inactive in non-targeted tissues. In addition we present the first example of a therapeutic effect achieved using smooth muscle-specific transcriptional targeting in the vessel wall. Promoter repression by the E2F/p56 fusion protein appeared to be so potent that we were unable to produce a CMV-driven version of the recombinant adenovirus with this transgene. By using the tissue-specific human smooth muscle ␣-actin (SMA) promoter that was inactive in our producer cell line, we circumvented this obstacle for the fusion construct. Thus, a tissue-specific strategy, as demonstrated here, should prove useful for producing viral constructs where transgene expression is inhibitory to viral growth or toxic to the producer cell line. The findings provide insights into the utility, as well as caveats, related to the use of transcriptional targeting. The fragment of the (SMA) promoter utilized in this study provided for transgene expression in carotid artery vascular smooth muscle without observable expression in bladder visceral smooth muscle, skeletal muscle or liver when administered systemically in vivo. The apparent specificity for vascular tissue was anticipated since additional sequences are required to express ␤-galactosidase in visceral smooth muscle in transgenic mice. 19 Recently, others 20, 21 have utilized adenoviral vectors containing the promoter from the murine smooth musclespecific gene SM22␣ linked to reporter genes to limit transgene expression to visceral and vascular smooth muscle. Both studies demonstrated that the SM22␣ constructs were able to confine transgene expression to the targeted tissue type, but in each case only a marker gene was examined, thereby preventing the assessment of the constructs for possible therapeutic applications.
The apparent discrepancy between the in vitro and in vivo efficacy of the SMA-driven Rb constructs points to an important issue. In vitro, both the Ad-SMA-p56 and Ad-SMA-E2F/p56 induced G1 arrest at levels comparable to those seen with a CMV-driven version of the p56 recombinant adenovirus. A different situation was found in vivo, where the Ad-SMA-E2F/p56 construct inhibited intimal hyperplasia by 37% in injured carotid arteries, similar to the outcome we had previously reported with CMV-driven constructs expressing full length human Rb and the p56 fragment (39% and 43%, respectively) 6 or that Chang et al 18 observed using a mutated form of murine Rb (42%). However, the levels of transgene expression obtained with the SMA promoter are lower compared with the CMV constructs, and the reduced expression may explain the lack of efficacy observed with the Ad-SMA-p56 construct in vivo. This may be understood to be a consequence of mass action, where a maximal growth inhibition is achieved for any Rb species when protein production exceeds a threshold level sufficient to saturate cellular regulatory mechanisms. Hence, above this threshold level, growth inhibition would be insensitive to differences in the inhibitory properties of the various Rb species. However, when transgene expression falls below the threshold level, the intrinsic inhibitory properties of the Rb species would be expected to determine the extent of anti-proliferative effects. Thus, the advantage of tissue specificity obtained with the SMA promoter appears to come at a cost of decreased expression that can lead to limited efficacy in vivo.
In the light of concerns regarding toxicity derived from transgene expression at non-targeted sites, the ability to limit the expression of potent growth inhibitors to specific tissues is an important step forward in the development of gene therapy strategies. In summary, we demonstrate VSMC-specific expression of transgenes and in vivo efficacy for the treatment of proliferative vascular dis-
Figure 4 3 H-thymidine incorporation assay for growth suppression by SMA versus CMV constructs in MB468 breast carcinoma and A7r5 vascular smooth muscle cells.Cultures were infected with increasing amounts of the indicated viruses for 48 h, followed by 3 H-thymidine labeling for 3 h and determination of 3 H-thymidine uptake. (a) MB468; (b) A7r5 cells. Results are the mean percentage (Ϯs.d.) of media-only treated controls versus the quantity of virus.
ease. In addition, we were able to overcome the intrinsic limitation of the SMA promoter by utilizing a more potent transgene. Therefore this study serves to illustrate both the virtues and the limitations that may arise when using a tissue-specific promoter for targeted gene delivery.
Materials and methods
Cell culture
The human embryonic kidney cell line 293 was used to generate and propagate recombinant adenoviruses, and were maintained in DME medium containing 10% defined, supplemented calf serum. C33A cells (human cervical carcinoma) were maintained in MEM NEAA Earl's medium supplemented with 10% fetal calf serum. MDA-MB468 (human breast carcinoma) cells were maintained in Kaighn's medium supplemented with 10% fetal calf serum (FCS). The rat smooth muscle cell line A7r5
Gene Therapy A7r5 cells were treated with 6.5 × 10 7 particles/ml and MB468 cells were treated with 1.1 × 10 9 particles/ml of the indicated viruses as described in Materials and methods. Cells were harvested and underwent FACS analysis to determine cell cycle distribution following treatment. The percentage of cells in G0/G1 versus S versus G2/M is presented.
was maintained in DME supplemented with 10% FCS. Primary human VSMCs were isolated and cultured as described previously. 22 Primary human umbilical venous endothelial cells (HUVECs) were isolated as described, 23 and grown in Medium 199 with 20% FBS.
Construction of plasmids and recombinant adenoviruses
Plasmids using the CMV promoter driving p56 (pCMVRb56), a phosphorylation-resistant p56 (pCMV-Rb56-5s) and the reporter E2F-CAT (pE2-CAT) have been described previously. 7 The pCMV-E2F/p56 plasmid replaced the p56 fragment of pCMV-Rb56 with the fragment of E2F fused to p56 as described below for making the virus. A fragment of the smooth muscle ␣-actin promoter (SMA) (bases Ϫ670 to +5) 10, 24 was isolated by PCR from a genomic library with 5' XhoI and AvrII and 3' XbaI, ClaI and HindIII restriction sites added for cloning purposes. The fragment was subcloned as an XhoI, Hind-III fragment into a plasmid for sequencing to verify base composition. The fusion construct E2F-p56 contains the DNA binding and heterodimerization domain of E2F-1 (bases 95-286) linked to p56 (aa 379-928 of full-length Rb) and was subcloned as a XbaI, ClaI fragment directly downstream of the smooth muscle ␣-actin promoter. This expression cassette was obtained as an AvrII, ClaI fragment and cloned into XbaI, ClaI digested pAd/ITR/IX to create the plasmid pAd-SMA-E2F/p56. cDNA s encoding either p56 or ␤-galactosidase were also subcloned into this plasmid vector as XbaI, ClaI fragments to create transfer plasmids encoding either p56 or ␤gal under the control of the human smooth muscle ␣-actin promoter. These plasmids consist of the adenovirus type 5 inverted terminal repeat (ITR), packaging signals and E1a enhancer, followed by the human smooth muscle ␣-actin promoter and either the 286-56 cDNA, the p56 cDNA or the ␤gal cDNA, each followed by Ad 2 sequence 4021-10 462 (which contains the E1b/protein IX poly A signal) in pBR322 background. The plasmids were linearized with NgoMI and co-transfected into 293 cells with the large fragment of ClaI digested rAd34. 25 Recombinant adenovirus (serotype 5) was produced and isolated by standard procedures and designated Ad-SMA-E2F/p56, Ad-SMA-p56, or Ad-SMA-␤gal, respectively. Control recombinant adenoviruses included empty control viruses containing only the smooth muscle ␣-actin or CMV promoters without any transgenes (Ad-SMA and Ad-CMV, respectively), CMV-driven, p56 encoding virus Ad-CMV-p56 and CMV-driven ␤gal (Ad-CMV-␤gal).
Promoter repression assay C33A cells were seeded at a density of 250 000 cells per plate and allowed to adhere overnight. Five micrograms of each plasmid pCMV-p56, pCMV-p56-5s, pCMV-E2F/p56 (E2F 286 fragment), or pCMV-E2F (286 fragment) plasmid were co-transfected with 5 g of pE2-CAT reporter construct and 2.5 g ␤-gal plasmid as duplicate samples. Cells were harvested after 72 h, and CAT activity was assayed from 20 l of cell extract. 26 TLCs were analyzed on a Phosphoimager SF (Molecular Dynamics, Sunnyvale, CA, USA). CAT activities were normalized for transfection efficiency variation according to ␤-gal activity of each sample.
Selective expression from SMA promoter MDA-MB468 (5 × 10 5 ) and 2.5 × 10 5 A7r5 were seeded in their normal growth media on six-well plates and allowed to attach overnight. Primary human VSMCs and HUVECs were synchronized by culturing in medium containing 0.5% FBS for 48-72 h. Recombinant adenovirus encoding ␤-galactosidase gene under either the control of the CMV promoter (Ad-CMV-␤gal) or the SMA promoter (Ad-SMA-␤gal) was used to infect the cells at the indicated MOI. For the MB468 or A7r5 cells, incubation continued for another 24 h in normal growth media. For the VSMCs and HUVECs, adenovirus infection was administered in the low serum media for 12 h, followed by a PBS wash and further incubation in normal growth media for 24-36 h. Media were aspirated off the plates, and cells were washed twice with PBS. Cells were fixed in a 1:10 dilution of formaldehyde (3.7%) in PBS for approximately 10 min, followed by two washes with PBS. X-gal stain 27 was then added to each well and incubated at room temperature for 24 h. Photographs of the cells were used to determine the extent of adenovirusmediated transgene expression.
Protein expression MDA-MB468 (5 × 10 5 ) and 1 × 10 6 A7r5 were seeded in six-well and 10-cm plates, respectively. Twenty-four hours later, the cells were infected with virus at the indicated doses. Forty-eight hours later, cells were washed once with PBS and harvested in lysis buffer (50 mm TrisCl pH 7.5, 250 mm NaCl, 0.1% NP-40, 50 mm NaF, 5 mm EDTA, 10 g/ml aprotinin, 10 g/ml leupeptin, and 1 mm PMSF). Protein concentration of the samples was determined by a Bradford assay (Bio-Rad Protein Assay kit), and equal amounts of protein (15 g/lane) were separated on an 8% Tris/glycine gel (Novex, San Diego, CA, USA) and transferred to nitrocellulose. Membranes were incubated with the monoclonal antibody 3C8 28 which binds to the carboxyterminal portion (exon 25-27) of Rb and p56, followed by secondary anti-mouse IgG antibody conjugated to horseradish peroxidase. p56 and E2F-p56 fusion proteins were visualized by chemiluminescence (ECL kit, Amersham, Piscataway, NJ, USA) on Kodak X-OMAT film.
Cellular proliferation:
3 H-thymidine uptake For MDA-MB468 cells, 5000 cells/well are plated in normal growth medium in a 96-well microtiter plate and allowed to incubate overnight at 37°C, 7% CO 2 . Viruses were serially diluted in growth medium and used to infect cells at the indicated doses for 48 h. 3 H-thymidine was then added (0.5 Ci/well, Amersham) and the cells were incubated at 37°C for another 3 h before harvest. A7r5 cells were seeded at 2000 cells/well in DME + 0.5% FCS. Virus was serially diluted in the seeding medium and used to infect the cells at the indicated doses. The A7r5 cells were not infected with virus until 48 h after seeding. Forty-eight hours after infection, the serum concentration was raised to 10% FCS and 2 Ci/well of 3 Hthymidine was added and incubation was continued for an additional 3 h before harvest. All cells were harvested by aspirating off medium from the wells, trypsinization of the cells, and harvest using a 96-well GF/C filter with a Packard Top count cell harvester. Results are plotted as the mean percentage (±s.d.) of untreated control 3 Hthymidine uptake versus dose of virus.
Flow cytometric analysis of cell cycle progression
A7r5 cells were seeded at a density of 1.5 × 10 5 cells/well in 10-cm dishes, while MDA-MB468 cells were seeded at 5 × 10 5 cells/well in six-well plates. A7r5 cells were serum starved in 0.5% serum for 48 h and then infected at an MOI of 100 in the low serum for an additional 24 h. Media was then switched to 10% serum growth media and incubated at 37°C for 16 h. MDA-MB468 cells were maintained in their normal growth medium and also infected at an MOI of 100 for approximately 40 h. Cells were harvested by trypsinization, fixed in 70% ethanol, and then stained for DNA content with 50 g/ml propidium iodide in PBS. Flow cytometry was performed on a Becton Dickinson FACS Scan and analyzed by Lysis II software.
In vivo administration
Ad-SMA-␤gal or Ad-CMV-␤gal was administered into Sprague-Dawley rats. 1 × 10 11 virus particles were delivered intravenously through the femoral vein to observe expression in the liver. 5 × 10 10 particles were delivered by direct injection into the skeletal muscle or urinary bladder. Tissues were harvested 3 days after delivery and fixed in 1% formaldehyde and 0.2% gluteraldehyde for 30 min. ␤-Galactosidase expression in tissue was visualized following a wash in PBS and incubation in 1 mg/ml Xgal solution for 12 h at room temperature.
Measurement of adenovirus effects on balloon catheter-induced injury in the rat carotid was based on the method described by Clowes et al. 29 The left carotid artery of adult male Sprague-Dawley rats underwent a de-endothelializing injury via abrasion as described preGene Therapy viously. 6 1 × 10 11 purified viral particles of the indicated adenoviruses or saline in a 100 l volume was then incubated in the injured artery for 20 min, after which the viral solution was withdrawn and the external carotid artery was ligated. Rats were killed after 3 days for ␤-galactosidase staining and at 14 days for measuring neointima formation. Injured segments of the left carotid arteries were harvested and analyzed as described previously. 6 
